14,200 Shares in Fractyl Health, Inc. (NASDAQ:GUTS) Bought by Renaissance Technologies LLC

Renaissance Technologies LLC bought a new position in Fractyl Health, Inc. (NASDAQ:GUTS) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 14,200 shares of the company’s stock, valued at approximately $61,000.

A number of other institutional investors also recently bought and sold shares of GUTS. American International Group Inc. bought a new position in Fractyl Health in the 1st quarter worth $9,911,000. M28 Capital Management LP bought a new position in Fractyl Health in the 1st quarter worth $13,735,000. Rhumbline Advisers bought a new position in Fractyl Health in the 2nd quarter worth $32,000. Finally, Massachusetts Financial Services Co. MA increased its stake in Fractyl Health by 2.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company’s stock worth $4,255,000 after buying an additional 25,829 shares in the last quarter.

Fractyl Health Trading Down 1.6 %

Shares of GUTS stock opened at $2.42 on Tuesday. Fractyl Health, Inc. has a 52-week low of $1.74 and a 52-week high of $14.50. The company has a current ratio of 7.46, a quick ratio of 7.46 and a debt-to-equity ratio of 0.40. The stock has a fifty day simple moving average of $2.69 and a two-hundred day simple moving average of $4.69.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.10. The business had revenue of $0.04 million during the quarter. As a group, analysts forecast that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jay David Caplan sold 65,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $2.90, for a total transaction of $188,500.00. Following the completion of the transaction, the insider now owns 30,484 shares in the company, valued at $88,403.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.